AI-generated analysis. Always verify with the original filing.
Inhibrx Biosciences, Inc. reported financial results for Q4 and fiscal year 2025, with net loss of $32.8 million ($2.11 per share) for Q4 and $140.1 million ($9.04 per share) for the year, compared to prior year net loss and net income respectively. Cash and cash equivalents stood at $124.2 million as of December 31, 2025, with $75.0 million gross proceeds from loan amendment on March 18, 2026.
Event Type
Disclosure
Mandatory
Variant
8-K
of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section
. Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Description 99.1 Press Release issued by Inhibrx Biosciences, Inc. on March 1 9 , 202 6 104 Cove
| Metric | Value | Basis |
|---|---|---|
| Total revenue | $0.00 | |
| Total revenue | $1.30 | |
| Research and development | $25.35 | |
| Research and development | $113.03 | |
| General and administrative | $5.57 | |
| General and administrative | $23.30 | |
| Net income (loss) | $-32.83 | |
| Net income (loss) | $-140.06 | |
| Basic EPS | $-2.11 | |
| Basic EPS | $-9.04 |
Debt / Financing